Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
نویسندگان
چکیده
We report a case of fingolimod-associated bilateral cystoid macular oedema in a patient with multiple sclerosis (MS). A 34-year-old female, diagnosed with MS at age of 30, developed bilateral blurred vision 5 days after initiation of fingolimod. She was misdiagnosed as optic neuritis initially and fingolimod was only discontinued 3 weeks after onset of her visual symptoms when OCT showed prominent bilateral cystoid macular oedema and subretinal fluid. Although her left corrected vision returned to 6/6, she had persistently decreased right visual acuity of 6/12 after 5 months. This paper aims to raise awareness among ophthalmologists and neurologists of the importance of early recognition of macular oedema associated with fingolimod.
منابع مشابه
[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
CASE REPORT A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and O...
متن کاملEvaluation of the Incidence of Macular Edema in Patients with Multiple Sclerosis Treated with Fingolimod
Purpose: To determine the incidence of macular edema in patients with MS treated with 0.5 mg Fingolimod. Methods: In this prospective descriptive-analytic study a total of 115 patients were enrolled. Patients underwent an ophthalmologic examination before starting the treatment. In the fourth month after starting the treatment for each patient, regardless of whether or not being marked, the oph...
متن کاملFingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?
Fingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing-remitting multiple sclerosis (MS). Several pivotal and real-world studies have demonstrated that fingolimod is associated with the development of macular edema (ME). Herein, we present a case of a diabetic MS patient who developed severe bilateral ME during fingolimod treatment. By means of this case study we provid...
متن کاملCystoid macular edema associated with fingolimod use for multiple sclerosis.
Fingolimod is the first oral drug approved by the US Food and Drug Administration for multiple sclerosis (MS). It is a sphingosine-1phosphate–receptor modulator that prevents lymphocyte egress from lymph nodes and enhances astrocyte function. In this retrospective case series, 4 eyes from 3 patients developed cystoid macular edema (CME) after initiating fingolimod therapy. The study was approve...
متن کاملAcute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis
Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator and the first oral therapy for relapsing-remitting multiple sclerosis. Its use has been complicated by a low rate of cystoid macular edema usually in the first 3 months after commencement of the medication. We report the case of a 34-year-old male with relapsing-remitting multiple sclerosis, who developed acute anterior uvei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 2012 شماره
صفحات -
تاریخ انتشار 2012